Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo
Malignant Pleural Mesothelioma
DRUG: Nintedanib|DRUG: Placebo
Progression-free survival, From randomization until progression or death, 6 months
Overall survival, From randomization until progression or death, 12 months|Overall Response Rate, Response according to modified RECIST, 6 months
This is a multicenter, prospective, double blinded, randomized, two-arm phase II trial aiming to evaluate nintedanib treatment as switch maintenance in patients with unresectable MPM.

After signing of the informed consent and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to:

* Arm A: twice daily nintedanib at a dose of 200 mg until progression or unacceptable toxicities.
* Arm B: matched placebo.

Response evaluation will be performed through CT scans every 8 weeks.